My management fails to fully capture scenario mean

My management fails to fully capture scenario means that for whatever reason they fail to properly advance the potential of Leronlimab and have to sell at a "fire sale" price of 2-3 billion. CYDY has such limited management infrastructure that I don't think they can take the drug very far on their own. Will they accept a BO? Will they find a suitable partner? How much will that partner cost? These are unknown questions and the right answers will be more challenging than most here expect. That being said, I believe 2-3 billion for shareholders at some point is the low end of my expectations for the value they will ultimately realize for shareholders. I hope that makes sense.